EMCURE PHARMACEUTICALS L Share Price
NiveshIQ
NSE: AJANTPHARM · Pharma
Ajanta Pharmaceuticals Ltd.
₹3,533.40▲ ₹13.40 (+0.38%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on AJANTPHARM. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Ajanta Pharmaceuticals Ltd.
Ajanta Pharma Limited is a pharmaceutical formulation company that engages in the development, manufacture, and marketing of specialty pharmaceutical finished dosages. The company offers a range of products, including chronic and acute therapies, branded generic products, and various dosage forms. It operates in India, Africa, Asia, the United States, and internationally, serving various therapeutic areas. Ajanta Pharma Limited has a strong presence in the Indian market and has been expanding its global footprint. The company has reported a revenue of ₹5776 Cr and a net income of ₹1135 Cr. Its recent Q1 profit of ₹334 Crore has led to a rise in its share price. With a strong product portfolio and expanding global presence, Ajanta Pharma Limited is well-positioned for growth in the healthca
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹4,208 Cr +12.40% | ₹4,648 Cr +10.50% | ₹5,454 Cr +17.30% |
| EBITDA Margin | 27.42% | 27.09% | 26.69% |
| Net Profit | ₹816.00 Cr +38.80% | ₹920.00 Cr +12.70% | ₹1,056 Cr +14.70% |
| EPS | ₹63.69 | ₹73.68 | ₹84.53 |
Annual figures in Indian Rupees (Crores). Source: BSE filings.
Recent News
Ajanta Pharma hosts investor meetings in New Delhi and Mumbai in September
Ajanta Pharma (NSE:AJANTPHARM): What Are the Upcoming Analyst Meets in September 2026?
🔒
+ 3 more stories about Ajanta Pharmaceuticals Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q1FY27 results: revenue ₹1, 626 Cr, PAT ₹334 Cr, EPS ₹26.75, EBITDA margin 30.4%. Growth context: revenue QoQ +14.4%, PAT QoQ +25.3%. Street verdict: strong beat, revenue surprise +7.8%, PAT surprise +17.2%.
Management's near-term growth strategy hinges on product launches, approvals, and therapy-mix improvement, which are exp...
FY26 (last completed FY): revenue ₹5, 454 Cr, PAT ₹1, 056 Cr, EBITDA margin 26.7%, EPS ₹84.53. Year-on-year: revenue YoY...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantEverything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for AJANTPHARM
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track AJANTPHARM alongside your other holdings
Unlock full AJANTPHARM research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Ajanta Pharmaceuticals Ltd.?
NiveshIQ detects active intelligence signals for Ajanta Pharmaceuticals Ltd. (AJANTPHARM) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Ajanta Pharmaceuticals Ltd.?
Ajanta Pharmaceuticals Ltd. operates in the Pharma sector with a market capitalisation of ₹3,791,796.3L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.